Personalized Cannabidiol Delivery Systems

A next-generation self-emulsifying cannabidiol technology integrating wearable devices, machine learning, and novel surfactant blends to optimize bioavailability, pharmacokinetics, and personalized treatment of neurological disorders.

The original patent disclosed self-emulsifying cannabidiol formulations, but limitations existed in terms of personalized delivery, bioavailability, and pharmacokinetics. The new inventive concept addresses these limitations by introducing wearable devices, machine learning algorithms, and novel surfactant blends to optimize cannabidiol treatment.

The inventive concept comprises a self-emulsifying cannabidiol composition, a wearable device for monitoring a subject's physiological response, and machine learning algorithms to predict optimal dosing regimens. The composition may include novel surfactant blends optimized for enhanced gut-brain axis interaction and administered via nasal spray or transdermal patch. A device for real-time monitoring of cannabidiol pharmacokinetics provides personalized dosing recommendations based on the subject's real-time cannabidiol levels. The inventive concept enables personalized treatment of neurological disorders, such as epilepsy, multiple sclerosis, and Parkinson's disease, in combination with neurostimulation therapies.

The new claims introduce wearable devices, machine learning algorithms, and novel surfactant blends, which are not obvious from the original patent. The integration of these components enables personalized cannabidiol delivery, optimized bioavailability, and real-time pharmacokinetics monitoring, making the inventive concept novel and non-obvious.

Alternative embodiments may include variations in wearable device design, machine learning algorithm implementation, and novel surfactant blend compositions. Additionally, the inventive concept could be adapted for use in veterinary medicine or for treating other diseases, such as cancer or inflammatory disorders.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the growing markets for personalized medicine and cannabidiol-based treatments. Target industries include pharmaceutical companies, biotech startups, and medical device manufacturers.